GlassScriptPhysician profile
Alia M Nunn
NPI 1447403530
$5,841.83
in general payments reported to CMS, 2019-2025
55 companies · $2,652 in 2025
The $2,652 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.01 · 2022: $253 · 2023: $1,216 · 2024: $1,699 · 2025: $2,652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,398 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,398.31 |
| Education | $167.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $626.33 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $420.89 | 2023-2025 | Enhertu, Imfinzi, Tagrisso |
| Merck Sharp & Dohme LLC | $346.42 | 2022-2025 | Keytruda, Welireg, Keytruda Qlex |
| Regeneron Healthcare Solutions, INC. | $262.22 | 2023-2025 | Libtayo |
| Astellas Pharma US INC | $214.65 | 2022-2025 | Xospata, Padcev, Vyloy |
| E.R. Squibb & Sons, L.L.C. | $188.81 | 2023-2025 | Reblozyl, Opdualag, Opdivo |
| Janssen Biotech, INC. | $187.30 | 2022-2025 | Darzalex, Balversa, Akeega |
| Gilead Sciences, INC. | $183.10 | 2022-2025 | Trodelvy |
| Celgene Corporation | $179.75 | 2023-2025 | Reblozyl, Pomalyst, Breyanzi |
| Daiichi Sankyo INC. | $179.53 | 2023-2025 | Enhertu, Vanflyta, Datroway |
| Abbvie INC. | $167.80 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $166.35 | 2022-2025 | Iclusig, Ninlaro |
| Incyte Corporation | $159.01 | 2022-2025 | Monjuvi, Pemazyre, Zynyz |
| Eisai INC. | $148.99 | 2022-2025 | |
| Pharmaessentia USA Corporation | $146.91 | 2023-2025 | Besremi |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $127.02 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $123.79 | 2023-2025 | Xpovio |
| Glaxosmithkline, LLC. | $123.58 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Lilly USA, LLC | $114.79 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $99.93 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $96.12 | 2022-2025 | Ultomiris |
| Exelixis INC. | $92.89 | 2025 | Cabometyx |
| Jazz Pharmaceuticals INC. | $88.19 | 2024-2025 | |
| Tersera Therapeutics LLC | $87.93 | 2022-2025 | Zoladex, Xermelo |
| Seagen INC. | $84.44 | 2023 | Padcev, Tukysa, Tivdak |
| Genzyme Corporation | $83.70 | 2023-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $75.90 | 2022-2023 | Imbruvica |
| Rigel Pharmaceuticals, INC. | $75.45 | 2022-2025 | Rezlidhia, Tavalisse, Gavreto |
| Emd Serono, INC. | $66.04 | 2023-2025 | Tepmetko |
| Pfizer INC. | $61.26 | 2024-2025 | |
| Beigene USA, INC. | $60.38 | 2023-2025 | Brukinsa, Tevimbra |
| Dendreon Pharmaceuticals LLC | $60.04 | 2024-2025 | Provenge |
| Stemline Therapeutics INC. | $60.02 | 2023-2025 | Orserdu |
| Genentech USA, INC. | $59.70 | 2024-2025 | Tecentriq, Polivy |
| Blueprint Medicines Corporation | $54.81 | 2024-2025 | Ayvakit |
| Servier Pharmaceuticals LLC | $45.99 | 2024-2025 | |
| Genmab U.S., INC. | $45.62 | 2024-2025 | Epkinly |
| Aveo Pharmaceuticals, INC. | $45.08 | 2023-2025 | Fotivda |
| Morphosys, US INC. | $42.04 | 2023 | Monjuvi |
| Adc Therapeutics America, INC. | $40.63 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $35.42 | 2024-2025 | Orgovyx |
| Puma Biotechnology, INC. | $31.40 | 2024 | |
| Mirati Therapeutics, INC. | $30.85 | 2023 | Krazati |
| Deciphera Pharmaceuticals INC. | $26.90 | 2024 | Qinlock |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.31 | 2023 | |
| Array Biopharma INC | $23.99 | 2023 | Mektovi, Paxlovid, Braftovi |
| Sun Pharmaceutical Industries INC. | $23.25 | 2024 | |
| Amgen INC. | $23.01 | 2021 | |
| Verity Pharmaceuticals INC. | $22.96 | 2024 | Trelstar |
| Ipsen Biopharmaceuticals, INC | $20.28 | 2025 | Onivyde |
| Recordati_rare_diseases_inc. | $19.81 | 2025 | Sylvant |
| Sobi, INC | $18.53 | 2025 | |
| Cti Biopharma Corp. | $18.40 | 2023 | Vonjo |
| Fennec Pharmaceuticals, INC. | $16.20 | 2025 | Fyarro |
| Pharmacosmos Therapeutics INC. | $13.12 | 2024 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alia Nunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.